Development of TMTP-1 targeted designer biopolymers for gene delivery to prostate cancer

John W McBride, Ashley S Massey, J McCaffrey, Cian M McCrudden, Jonathan A Coulter, Nicholas J Dunne, Tracy Robson, Helen O McCarthy

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)
361 Downloads (Pure)


Designer biopolymers (DBPs) represent state of the art genetically engineered biomacromolecules designed to condense plasmid DNA, and overcome intra- and extra- cellular barriers to gene delivery. Three DBPs were synthesized, each with the tumor molecular targeting peptide-1 (TMTP-1) motif to specifically target metastases. Each DBP was complexed with a pEGFP-N1 reporter plasmid to permit physiochemical and biological assay analysis. Results indicated that two of the biopolymers (RMHT and RM3GT) effectively condensed pEGFP-N1 into cationic nanoparticles< 100nm and were capable of transfecting PC-3 metastatic prostate cancer cells. Conversely the anionic RMGT DBP nanoparticles could not transfect PC-3 cells. RMHT and RM3GT nanoparticles were stable in the presence of serum and protected the cargo from degradation. Additionally it was concluded that cell viability could recover post-transfection with these DBPs, which were less toxic than the commercially available transfection reagent Lipofectamine® 2000. With both DBPs, a higher transfection efficacy was observed in PC-3 cells than in the moderately metastatic, DU145, and normal, PNT2-C2, cell lines. Blocking of the TMTP-1 receptors inhibited gene transfer indicating internalization via this receptor. In conclusion RMHT and RM3GT are fully functional DBPs that address major obstacles to gene delivery and target metastatic cells expressing the TMTP-1 receptor.

Original languageEnglish
Pages (from-to)144-153
Number of pages10
JournalInternational Journal of Pharmaceutics
Issue number1-2
Early online date21 Jan 2016
Publication statusPublished - 16 Mar 2016


Dive into the research topics of 'Development of TMTP-1 targeted designer biopolymers for gene delivery to prostate cancer'. Together they form a unique fingerprint.

Cite this